Autopsy report · NCT03746704
Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies
Cause of deathFunding or business
“Business decision”
Life of this trial
- Registered 10 months before it started.
- Ran for about 1 year 10 months before it stopped.
- 2 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Advanced PD-L1 Positive Malignancies
- Interventions
- 89Zr˗DFO˗REGN3504
- Participants
- 2
- Sites
- 2
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.